Hawkeye Bio granted U.S patent for graphene biosensor platform

The patented technology utilizes pristine graphene particles functionalized with optical reporter systems that respond to the presence of specific protease biomarkers. When exposed to target biological molecules, the biosensors convert biochemical interactions into measurable optical signals, enabling precise detection of molecular activity associated with disease.

Hawkeye Bio has announced that the United States Patent and Trademark Office (USPTO) has granted U.S. Patent No. 12,461,102 titled “Pristine Graphene Based Biosensor for Biomarker Detection and Related Core Particles, Materials Compositions Methods and Systems.” The patent protects Hawkeye Bio’s proprietary graphene-based biosensor platform technology designed to detect biological molecules through highly sensitive optical signaling mechanisms.The patented technology utilizes pristine graphene particles functionalized with optical reporter systems that respond to the presence of specific protease biomarkers. When exposed to target biological molecules, the biosensors convert biochemical interactions into measurable optical signals, enabling precise detection of molecular activity associated with disease.

Read More Graphene-Info – Graphene industry portal